预约演示

Creative Medical taps CRO Syneos to run Type 1 diabetes cell therapy study

2023-03-09

细胞疗法临床研究

Last month, Syneos launched a decentralized clinical trial site network.

Biotech CreaSyneosedical Technology has tapped Syneos Health to run a phase 1/2 randomized trial of its cell therapy for the potential treatment of Type 1 diabetes.

Biotech Creative Medical Technology01 recently Syneos Healthgreen light from the FDA to enter a trial on its safety and efficacy, which is expected Type 1 diabetes end of the month.

Creative Medical is touted asCELZ-201a new approach to leveraging the self-renewaFDAbilities and low antigenicity of cells taken from perinatal tissue, the Phoenix-based company said in a March 7 press release. Financial details of the partnership weren’t disclosed.

“The commencement of this first-in-country clinical trial is a milestone event for Creative Medical Technology Holdings and a reflection of our commitment to developing novel therapies with the potential to address areas of high unmet medical need,” Creative's CEO Timothy Warbington said in the release.

Last month, Syneos launched a decentralized clinical trial site network with the aiCreative Medical Technology Holdingsogy solutions." Initially launching in the U.S. and Canada, the network will cover therapeutic areas as varied as internal and geneCreativecine, family practice, neurology, endocrinology, pediatrics and psychiatry, to name a few.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构